Cargando…

First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study()

AIM: The multicentre non-interventional AVANTI study assessed safety, effectiveness and patient-reported outcomes with approved first-line bevacizumab-containing regimens for HER2-negative locally recurrent/metastatic breast cancer (LR/MBC) in German routine oncology practice. METHODS: Eligible pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Volkmar, Ruhnke, Markus, Hoffmann, Oliver, Grafe, Andrea, Tomé, Oliver, Fett, Werner, Bruch, Harald-Robert, Sommer-Joos, Ann-Katrin, Schneeweiss, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424587/ https://www.ncbi.nlm.nih.gov/pubmed/34488065 http://dx.doi.org/10.1016/j.breast.2021.08.014

Ejemplares similares

Avanti coi superconduttori
por: Lena, R
Publicado: (1985)

Festino nella sera del Giovedi Grasso avanti cena
por: Banchieri, Adriano, d. 1634
Publicado: (1995)

La "camera a scintilla" porterà avanti gli studi atomici
por: Coen, A
Publicado: (1964)

LHC, via libera da Strasburgo "L'esperimento vada avanti"
Publicado: (2008)

Personnel scheduling using an integer programming model- an application at Avanti Blue-Nile Hotels
por: Kassa, Biniyam Asmare, et al.
Publicado: (2013)

Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients
por: Sehouli, Jalid, et al.
Publicado: (2021)

Misura dell'asimmetria avanti-indietro del quark s alla risonanza della Z in DELPHI
por: Cossutti, Fabio
Publicado: (1996)

Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI)
por: Chuchalin, Alexander, et al.
Publicado: (2013)

Frazioni di decadimento semileptoniche e asimmetria avanti-indietro del quark b con il rivelatore ALEPH
por: Marinelli, N
Publicado: (1997)

Misura dell'asimmetria avanti-indietro in eventi $e^{+}e^{-} \to b\overline{b}$ con l'apparato OPAL al LEP
por: Xella, S M
Publicado: (1995)

Misura inclusiva dell'asimmetria avanti-indietro in eventi $e^+ e^- \to b \bar b$ nel rivelatore DELPHI a LEP
por: Passeri, Antonio
Publicado: (1994)

Bevacizumab in the treatment of HER2-negative breast cancer
por: Lorusso, Vito
Publicado: (2008)

Bevacizumab in HER2-negative inflammatory breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?
por: Kümmel, Sherko, et al.
Publicado: (2018)

Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies
por: Yamamoto, Yutaka, et al.
Publicado: (2022)

Misura della asimmetria avanti-indietro nel processo $e^{+}e^{-} \to b-\overline{b}$ con il rivelatore OPAL al LEP
por: Montanari, A
Publicado: (1995)

Costruzione e studio di un calorimetro a zero gradi per la misura dell'energia in avanti dell'esperimento ALICE
por: Siddi, E
Publicado: (1998)

A Real‐World Multicentre Retrospective Study of Paclitaxel‐Bevacizumab and Maintenance Therapy as First‐Line for HER2‐Negative Metastatic Breast Cancer
por: Gamucci, Teresa, et al.
Publicado: (2016)

Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer
por: Redondo, Andrés, et al.
Publicado: (2014)

Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)
por: Thill, Marc, et al.
Publicado: (2022)

Identificazione di elettroni e fotoni nella regione avanti: indietro dell'esperimento UA2' al collider $p\overline{p}$ del CERN
por: Pennacchio, Elisabetta
Publicado: (1988)

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
por: Grüntkemeier, Lisa, et al.
Publicado: (2022)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
por: Huober, Jens, et al.
Publicado: (2010)

Neoadjuvant pertuzumab in non-metastatic HER2-positive breast tumors: Multicentric study in Peru (NeoHer)
por: Falcon, Silvia, et al.
Publicado: (2022)

Longitudinal Changes in Retinal Nerve Fiber Layer Thickness Evaluated Using Avanti Rtvue-XR Optical Coherence Tomography after 23G Vitrectomy for Epiretinal Membrane in Patients with Open-Angle Glaucoma
por: Lyssek-Boroń, Anita, et al.
Publicado: (2017)

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
por: Burger, Michael C., et al.
Publicado: (2017)

Psicocibernética 2000 : el mejor plan de superación personal para alcanzar el éxito
por: Sommer, Bobbe L.
Publicado: (1998)

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2011)

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
por: Sánchez-Rovira, P., et al.
Publicado: (2013)

Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
por: Haugen, Mads H., et al.
Publicado: (2021)

Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
por: Chen, Clara, et al.
Publicado: (2015)

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
por: Fehm, Tanja, et al.
Publicado: (2007)

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
por: Fabi, Alessandra, et al.
Publicado: (2012)

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer
por: Mahner, Sven, et al.
Publicado: (2015)

CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer
por: Sengupta, S., et al.
Publicado: (2015)

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
por: Quintela-Fandino, Miguel, et al.
Publicado: (2020)

Misura della sezione d'urto e dell'asimmetria avanti-indietro per il processo $e^{+} e^{-} \to \tau^{+} \tau^{-}$ al polo della Z0 all'esperimento L3 a LEP
por: Passaleva, G
Publicado: (1995)

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
por: Sun, Zhengwu, et al.
Publicado: (2020)

Efficacy Evaluation of Bevacizumab Combined with Capecitabine in the Treatment of HER2-Negative Metastatic Breast Cancer: A Meta-Analysis
por: Hu, Yiyi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4cvd8o9ihvp070p1gm8pi0qnt6